AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ARROWHEAD PHARMACEUTICALS, INC. Director's Dealing 2009

Oct 13, 2009

31071_dirs_2009-10-13_60b0c8f1-77ae-4de1-a27d-4f6aada5ec8e.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ARROWHEAD RESEARCH CORP (ARWR)
CIK: 0000879407
Period of Report: 2009-10-08

Reporting Person: STEWART R BRUCE (Director, Executive Chairman)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2009-10-08	Stock Option	$0.51	A	322000	Acquired	2019-10-08	Common Stock (322000)	Direct

Footnotes

F1: 11% of the option award would be vested at the time of grant and the remaining 89% would vest ratably on a quarterly basis over the next two years.